EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives

Ioanna A Anastasiou iD, Dimitris Kounatidis iD, Natalia G Vallianou iD, Eleni Rebelos, Irene Karampela iD, Maria Dalamaga iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ioanna A Anastasiou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Ho…. Hauptthemen laut MEDLINE: Clonal Hematopoiesis, Cardiovascular Diseases, Metabolic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the expansion of hematopoietic stem cells harboring leukemogenic mutations in the absence of overt malignancy. Strongly associated with advancing age, CHIP is detected by next-generation sequencing of peripheral blood in more than 20% of individuals over 80, most commonly through mutations in DNMT3A, TET2, ASXL1, and PPM1D. While CHIP confers over a four-fold increased risk of hematologic malignancy, it has recently emerged as a key determinant of cardiometabolic health. Epidemiological data indicated a 40% higher cardiovascular disease (CVD) risk events and a 34% increase in all-cause mortality among CHIP carriers, with specific mutations and larger clone sizes conferring greater cardiovascular burden. Preclinical studies have shown that macrophages deficient in TET2 or DNMT3A drive interleukin (IL)-1β/IL-6 inflammasome activation, thereby promoting atherosclerosis and metabolic dysfunction, whereas the JAK2V617F mutation accelerates thrombosis. CHIP integrates into a broader network of dysregulation encompassing adiposity and inflammaging, which underlies its association with diverse comorbidities, including type 2 diabetes (T2D), chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). Multi-omics approaches have identified epigenetic and proteomic signatures correlated with CHIP expansion, providing potential biomarkers for risk stratification. Despite growing evidence of its systemic impact, CHIP screening remains limited to research settings. Emerging therapeutic strategies, including inflammasome inhibition, STING modulation, and epigenetic restoration, highlight its potential as a modifiable risk factor. This narrative review synthesizes current epidemiological, mechanistic, and translational insights, framing CHIP as an emerging causal factor in cardiometabolic disease and as a promising target for precision medicine in aging populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clonal HematopoiesisCardiovascular DiseasesMetabolic DiseasesHumansAnimalsMutationDNA Methyltransferase 3ADioxygenases

Stichwörter der Autor:innen

CHIPagingatherosclerosiscardiometaboliccardiovascularclonal hematopoiesisclonal hematopoiesis of indeterminate potentialdiabetesinflammationobesity

Substanzen

DNA Methyltransferase 3ADioxygenases

Autor:innen und Institutionen

  • Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece.
  • Department of Pharmacology, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • First Department of Internal Medicine, Sismanogleio General Hospital, 15126 Athens, Greece.
  • Turku PET Centre, University of Turku, 20014 Turku, Finland.
  • Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
  • Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

ORCID-Profile: Ioanna A Anastasiou, Dimitris Kounatidis, Natalia G Vallianou, Irene Karampela, Maria Dalamaga

Zitieren

APA

Anastasiou, I. A., Kounatidis, D., Vallianou, N. G., Rebelos, E., Karampela, I., & Dalamaga, M. (2025). Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010233

Vancouver

Anastasiou IA, Kounatidis D, Vallianou NG, Rebelos E, Karampela I, Dalamaga M. Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010233

BibTeX
@article{Anastasiou2025,
  author = {Anastasiou, Ioanna A and Kounatidis, Dimitris and Vallianou, Natalia G and Rebelos, Eleni and Karampela, Irene and Dalamaga, Maria},
  title = {Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010233}
}
Kostenlos starten →